Literature DB >> 9766261

Different effects of octreotide by continuous night infusion at increasing rate or by evening injections at different times on morning hyperglycemia and growth hormone levels in insulin-dependent diabetic patients.

M Lunetta1, M Di Mauro, R Le Moli.   

Abstract

The effect of octreotide on morning hyperglycemia and GH levels was evaluated in eight insulin-dependent diabetic patients. Octreotide (50 mcg) was administered through subcutaneous injections at different hours (20:00, 22:00 and 24:00 h) or through continuous subcutaneous night infusion from midnight to 08:00 at increasing rate between 03:00 and 08:00 h. After octreotide injection at midnight we noticed a sharp decrease of both glycemia (p < 0.005) and GH (p < 0.05) at 04:00 h, but not at 08:00 h. Only the night continuous infusion at increasing rate was able to reduce glycemia and GH at 04:00 and at 08:00 h (p < 0.001 and p < 0.01 respectively). The injections of octreotide at 20:00 and 22:00 h lowered GH values at 24:00 h (p < 0.01 and p < 0.05 vs insulin alone) but did not show any significant effect on blood glucose levels and GH at 04:00 and 08:00 h. In conclusion, only the continuous subcutaneous night infusion of octreotide at increasing rate during the last hours of the night was able to reduce simultaneously morning hyperglycemia and GH levels in insulin-dependent diabetic patients, whereas evening subcutaneous injections at different times did not show any appreciable effect.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766261     DOI: 10.1007/BF03347326

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

2.  Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.

Authors:  S E Christensen; J Weeke; H Orskov; N Møller; A Flyvbjerg; A G Harris; E Lund; J Jørgensen
Journal:  Clin Endocrinol (Oxf)       Date:  1987-09       Impact factor: 3.478

Review 3.  The dawn phenomenon: nocturnal blood glucose homeostasis in insulin-dependent diabetes mellitus.

Authors:  G Perriello; P De Feo; G B Bolli
Journal:  Diabet Med       Date:  1988-01       Impact factor: 4.359

4.  Increased overnight growth hormone concentrations in diabetic compared with normal adolescents.

Authors:  J A Edge; D B Dunger; D R Matthews; J P Gilbert; C P Smith
Journal:  J Clin Endocrinol Metab       Date:  1990-11       Impact factor: 5.958

5.  Continuous subcutaneous octreotide infusion: dose-response relationships between metabolic effects and octreotide clearance in patients with insulin-dependent (type 1) diabetes.

Authors:  K Osei; T M O'Dorisio; W B Malarkey; S Cataland
Journal:  J Lab Clin Med       Date:  1991-07

6.  Sequence of events during development of the dawn phenomenon in insulin-dependent diabetes mellitus.

Authors:  P J Campbell; G B Bolli; P E Cryer; J E Gerich
Journal:  Metabolism       Date:  1985-12       Impact factor: 8.694

7.  Growth hormone and somatomedin in insulin-dependent diabetes mellitus.

Authors:  J M Horner; S F Kemp; R L Hintz
Journal:  J Clin Endocrinol Metab       Date:  1981-12       Impact factor: 5.958

8.  Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers.

Authors:  R S Aarsen; G J Bruining; W F Grose; R van Strik; S W Lamberts; A G Harris
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1987

9.  Suppression of sleep-induced growth hormone secretion by anticholinergic agent abolishes dawn phenomenon.

Authors:  M B Davidson; M D Harris; F H Ziel; C S Rosenberg
Journal:  Diabetes       Date:  1988-02       Impact factor: 9.461

10.  Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.

Authors:  K Osei; T M O'Dorisio; W B Malarkey; E L Craig; S Cataland
Journal:  Diabetes       Date:  1989-06       Impact factor: 9.461

View more
  1 in total

Review 1.  Circadian Variation in Efficacy of Medications.

Authors:  James C Walton; William H Walker; Jacob R Bumgarner; O Hecmarie Meléndez-Fernández; Jennifer A Liu; Heather L Hughes; Alexis L Kaper; Randy J Nelson
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.